Retinal laser photocoagulation is a proven, effective treatment for various retinal disorders, including diabetic retinopathy, retinal vein occlusions, and sickle cell retinopathy. To minimize iatrogenic retinal damage while maintaining therapeutic effects, retinal laser technology has evolved significantly since its introduction in ophthalmology more than half a century ago. These innovations have included both optimizations of laser parameters in addition to the development of novel laser delivery systems. This review summarizes recent innovations in retinal laser technology, including subthreshold micropulse laser, selective retinal therapy and nanosecond laser, innovative modes of laser delivery including pattern scanning laser, endpoint management, navigated laser, and newly described photo-mediated ultrasound therapy.
Introduction
Lasers are designed to produce a monochromatic, highly directional light beam with photons in phase and at the same frequency. These properties of lasers allow them to be a critical therapeutic tool in many fields of medicine, particularly in retinal diseases ( Figure 1 ). Lasers have been used to treat various retinal conditions, including proliferative diabetic retinopathy, diabetic macular edema, central serous chorioretinopathy, central and branch retinal vein occlusions, sickle cell retinopathy, and age-related macular degeneration, since it was first described over 55 years ago [1] . Moreover, retinal laser photocoagulation has been the gold-standard of care for some of these retinal diseases for almost half a century.
The precise biological mechanism by which laser therapy leads to improvement of retinal diseases remains an area of active investigation. One hypothesis is that photocoagulation destroys the most metabolically active cells, the photoreceptors, to relieve the imbalance between supply and demand of oxygen to decrease retinal hypoxia and subsequently causes down-regulation of angiogenic factors [2] [3] . Conventional retinal photocoagulation is typically performed with a 514-nm or 532-nm continuous wave (cw) laser using pulse durations from 100 to 200 milliseconds (ms), spot sizes from 60 to 500 micrometers, and powers from 100 to 750 milliwatts (mW). It produces detectable gray-white lesions in the retina as a desired therapeutic endpoint of treatment due to the thermal coagulation necrosis. These thermal effects are not only valuable for treating retinal diseases but also carrying significant side effects, such as permanent retinal scarring and decreased peripheral, color, and night vision [4] .
Over the last couple decades, innovative laser modalities have significantly evolved, with refined laser parameters including laser wavelength, pulse duration and laser beam size, as well as novel laser delivery systems to minimize collateral tissue damage, improve therapeutic effects, and alleviate patients' discomfort [5] [6]. The purpose of this review is to summarize recent novel laser technologies for the treatment of retinal diseases.
Pattern Scanning Laser
An integrated semi-automatic pattern scanning laser photocoagulation system PASCAL ® (PAttern SCAnning Laser) photocoagulator was first described by Blumenkranz et al. in 2005 [7] . This system is designed to rapidly deliver laser pulses of 10 -30 millisecond in a predetermined pattern array which allows for multiple spots of photocoagulation to be rapidly scanned with a single foot pedal While some studies have found it to be less effective than conventional laser, these studies have not accounted for the significant increase in the number of laser spots that are required to achieve an equivalent treatment area with shorter pulse duration laser burns [14] [15] [16] . PASCAL ® is also an ideal laser system to treat patients with macular edema. Since patterns for macular photocoagulation can be predetermined as rings or arcs with a central foveal exclusion zone, PASCAL can help to make sure that no laser burns will be placed closer than a preset distance from the center of the foveal avascular zone [17] [18].
Endpoint Management
It is widely considered that the refined laser settings are favorable to reduce collateral tissue damage while retaining the therapeutic effects of laser. A model-based titration algorithm termed "Endpoint Management" (EpM) has been developed for quantifying laser dosimetry predictably to precisely optimize the laser power and pulse duration to achieve subvisible retinal laser therapy [19] . 
Navigated Laser
Another novel laser delivery system Navigated laser photocoagulation with retinal eye tracking (NAVILAS ® ; OD-OS GmbH, Berlin) has been developed to offer more accurate and less painful laser photocoagulation using pre-planned, image-guided photocoagulation [25] . The navigated laser system combines a fundus imaging system with a laser treatment device and allows various imaging modalities, including infrared, color and fluorescein angiography, to be integrated with laser treatment of the retina. The NAVILAS ® laser system fundamentally differs from other manual-technique laser devices since it is a fundus camera-based system instead of a slit lamp-based laser system. With the 
Subthreshold Diode Micropulse Laser
A novel technology termed subthreshold diode micropulse (SDM) photocoagulation was developed to treat retinal vascular disorders while minimizing collateral tissue damages using an 810-nm diode laser with micropulse duration [27] .
SDM uses a continuous-wave laser which is divided into microsecond pulses to localize the thermal effects to the level of the retinal pigment epithelium (RPE), which lies between the neural retina and the choroidal layer and plays a vital role in the maintenance of the photoreceptor function. The term "subthreshold" refers to laser energy applied without visible intraretinal damage or scarring either during or after treatment. Laser burns produced by SDM do not appear on fluorescein angiography, which indicates the intact RPE tight junctions [28] . With micropulse duration, the increase in temperature of the neurosensory retina will not exceed the protein denaturation threshold when the minimum laser irradiance required for activation of the RPE is applied. Sublethally injured RPE is hypothesized to modify the expression of various cytokines that regulate angiogenesis and vascular leakage, which is believed to be responsible for the therapeutic effects of SDM [29] .
Using a micropulse mode, laser is delivered with a train of short repetitive pulses separated by variable quiet intervals achieved by alteration of the duty cycle of laser. A duty cycle is the fraction of a period of time when the laser is "on". This "on" time is the duration of each micropulse (typically 100 μs to 300 μs), and the "off" time (typically 1700 μs to 1900 μs) is the interval between micropulses, which allows for reduction of originated heat [30] . When a low duty cycle is used, commonly set at 5% for SDM, the "on" time is short enough to allow the tissue return to baseline temperature between pulses, which also limits the time for thermal dissipation between each pulse thereby reducing collateral damage. To achieve the beneficial effects of laser, repeated pulses are added, allowing the tissue to return to baseline temperature between pulses.
The absence of collateral laser damage with micropulse laser may allow high-density therapy. Low-intensity/high-density micropulse laser is particular favorable for DME or ischemic retina with PDR. SDM was demonstrated as equal or superior to conventional laser photocoagulation for the treatment of 
Selective Retinal Therapy (SRT)
Conventional laser photocoagulation has limited use in many retinal diseases involving the macular such as age-related macular degeneration (AMD), DME, and CSCR due to collateral thermal damage which can cause severe loss of vision. These diseases are considered to be associated with the dysfunction of RPE.
Selective retinal therapy (SRT) with microsecond pulses has been developed to selectively induce changes in the RPE so that the laser-induced thermal damage to surrounding tissue can be avoided, particularly to the neurosensory retina [34] . With microsecond pulses, produced heat is confined to the absorber site, An alternative mode of SRT has been developed which allows for the use of a currently available laser system using a rapidly scanning CW laser to produce microsecond laser dwell times to achieve the selective treatment of RPE cells [38] . . In an international, multicenter clinical trial, SRT was performed on patients suffering from DME, CSCR, and drusen associated with AMD. One-year follow up after SRT, most of the patients underwent a reduction in symptoms [37] .
Retinal Rejuvenation Therapy
Age Moreover, in an object with spherical or cylindrical shape (e.g. a blood vessel), the laser-induced photoacoustic wave can converge into the center and achieve a significantly high acoustic pressure and produce cavitation, which is referred to as "cold bubbles" and has been observed in cells. The addition of a laser pulse to an existing ultrasound field can significantly improve the likelihood of localized inertial cavitation [47] .
Taking advantage of the high optical absorption of hemoglobin, PUT can selectively target microvessels without causing unwanted damage to the surrounding tissue ( Figure 5 ). In PUT, the required energy levels of both ultrasound and laser are significant lower than those used in previous therapies.
Therefore, no significant temperature rise is induced and thermal damage can be effectively avoided. Moreover, PUT is noninvasive and agent-free unlike PDT.
Pre-clinical studies in rabbits has shown that PUT holds significant potential for the management retinal and choroidal vascular diseases in future, but further investigation and clinical trials are needed.
Conclusions
Retinal laser therapy has been playing a critical role in the care for numerous retinal diseases for over 50 years. Conventional laser photocoagulation has significant side effects. There have been significant modifications and novel laser modalities developed to achieve better outcomes while minimizing the side effects of conventional retinal laser therapy (Table 1) . The development of these novel technologies demonstrates that lasers will continue to play a critical role in the treatment of retinal diseases. In the future, further investigations will also be made to evaluate the effect of combined therapy. Concurrent therapy of laser and pharmacologic agents has been shown to not be simply additive, but the laser and pharmacotherapies can affect the outcomes of one another. More recently, a newly described laser technology PUT combines laser irradiation with ultrasound bursts shows great potential for the management of neovascular diseases [48] . Continuing innovations in laser technology and improved understanding of laser-retinal interactions make us believe that laser therapy will continue to play a critical role in the treatment of retinal diseases for many years to come.
